ABSTRACT
ObjectiveTo evaluate the curative effect of supplementedGanmai-Dazaodecoction for malignant tumor correlation with depression.MethodsA total of 98 patients with malignant tumor-related depression were divided into a treatment group and acontrol group according to the random number table. The control group were treated with flupentixol and melitracen tablets (Deanxit) combined with conventional treatment, the treatment group were treated with oral administration of traditional Chinese medicine supplemented Ganmai-Dazaodecoction combined with conventional treatment for 8 weeks. The Hamilton Depression Scale (HAMD) was used to evaluate the curative effect.ResultsThe effective rate showed no significant difference between the treatment groupand the control group (79.59%vs.75.51%;χ2=0.059,P=0.809). HAMD scores in both groups were significantly decreased after the treatment than before treatment (12.8±3.4 vs. 29.4±4.7 in the treatment group, 12.3±3.6vs.28.7±4.5 in the controlgroup, allP<0.05), there was no significant difference in HAMD scores after the treatment between the treatment group and the control group (t=0.707,P=0.481). ConclusionCurative effect of supplementedGanmai-Dazaodecoction is equal to flupentixol andmelitracen tablets in patients with malignant tumor-related depression.
ABSTRACT
Objective To discuss the clinical value of 18 F-FDG PET imaging in postoperative and postradiotherapeutic intracranial glioma during follow up study. Methods 18F-FDG PET imaging in 16 cases of postoperative and postradiotherapeutic intracranial glioma was compared with CT and/or MRI. Results Contrast CT or MRI showed prominent irregular circular or nodular enhancement in 14 of 16 cases (64%),can not distinguished from postopertative changes, radioinjury, tumor residue or recurrence.Among them, 9 cases showed tumor residue or recurrence based on significantly increased FDG uptake, 5 were confirmed by pathologic study. The other 5 cases of cerebral necrosis and 2 cases with postoperative cerebral malacia demonstrated FDG uptake defects. Conclusions 18F-FDG PET imaging has significant dominance in characterizing lesions for differentiating residue or recurrent disease from radioinjury in intracranial glioma. Combined with CT and MRI can provide both anatomical and functional informations.